Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/112687
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Food Science and Nutrition-
dc.contributorResearch Centre for Chinese Medicine Innovation-
dc.contributorResearch Institute for Smart Ageing-
dc.contributorResearch Institute for Future Food-
dc.creatorLi, L-
dc.creatorXu, N-
dc.creatorHe, Y-
dc.creatorTang, M-
dc.creatorYang, B-
dc.creatorDu, J-
dc.creatorChen, L-
dc.creatorMao, X-
dc.creatorSong, B-
dc.creatorHua, Z-
dc.creatorTang, B-
dc.creatorLee, SMY-
dc.date.accessioned2025-04-28T07:53:19Z-
dc.date.available2025-04-28T07:53:19Z-
dc.identifier.issn1933-7213-
dc.identifier.urihttp://hdl.handle.net/10397/112687-
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.rights© 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rightsThe following publication Li, L., Xu, N., He, Y., Tang, M., Yang, B., Du, J., Chen, L., Mao, X., Song, B., Hua, Z., Tang, B., & Lee, S. M.-y. (2025). Dehydroervatamine as a promising novel TREM2 agonist, attenuates neuroinflammation. Neurotherapeutics, 22(2), e00479 is available at https://doi.org/10.1016/j.neurot.2024.e00479.en_US
dc.subject19,20-Dehydroervatamineen_US
dc.subjectNeuroinflammationen_US
dc.subjectNF-κBen_US
dc.subjectNLRP3en_US
dc.subjectTREM2en_US
dc.titleDehydroervatamine as a promising novel TREM2 agonist, attenuates neuroinflammationen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume22-
dc.identifier.issue2-
dc.identifier.doi10.1016/j.neurot.2024.e00479-
dcterms.abstractMicroglia play a dual role in neuroinflammatory disorders that affect millions of people worldwide. These specialized cells are responsible for the critical clearance of debris and toxic proteins through endocytosis. However, activated microglia can secrete pro-inflammatory mediators, potentially exacerbating neuroinflammation and harming adjacent neurons. TREM2, a cell surface receptor expressed by microglia, is implicated in the modulation of neuroinflammatory responses. In this study, we investigated if and how Dehydroervatamine (DHE), a natural alkaloid, reduced the inflammatory phenotype of microglia and suppressed neuroinflammation. Our findings revealed that DHE was directly bound to and activated TREM2. Moreover, DHE effectively suppressed the production of pro-inflammatory cytokines, restored mitochondrial function, and inhibited NLRP3 inflammasome activation via activating the TREM2/DAP12 signaling pathway in LPS-stimulated BV2 microglial cells. Notably, silencing TREM2 abolished the suppression effect of DHE on the neuroinflammatory response, mitochondrial dysfunction, and NF-κB/NLRP3 pathways in vitro. Additionally, DHE pretreatment exhibited remarkable neuroprotective effects, as evidenced by increased neuronal viability and reduced apoptotic cell numbers in SH-SY5Y neuroblastoma cells co-cultured with LPS-stimulated BV2 microglia. Furthermore, in our zebrafish model, DHE pretreatment effectively alleviated behavioral impairments, reduced neutrophil aggregation, and suppressed neuroinflammation in the brain by regulating TREM2/NF-κB/NLRP3 pathways after intraventricular LPS injection. These findings provide novel insights into the potent protective effects of DHE as a promising novel TREM2 agonist against LPS-induced neuroinflammation, revealing its potential therapeutic role in the treatment of central nervous system diseases associated with neuroinflammation.-
dcterms.abstractGraphical abstract: [Figure not available: see fulltext.]-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationNeurotherapeutics, Mar. 2025, v. 22, no. 2, e00479-
dcterms.isPartOfNeurotherapeutics-
dcterms.issued2025-03-
dc.identifier.scopus2-s2.0-85210389810-
dc.identifier.eissn1878-7479-
dc.identifier.artne00479-
dc.description.validate202504 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextThe Science and Technology Development Fund (FDCT) of Macao SAR (No.: 0058/2019/A1 and 0016/2019/ AKP); Shenzhen-Hong Kong-Macao Science and Technology Innovation Project (Category C) of Shenzhen Science and Technology Innovation Committee (No.: EF038/ICMS-LMY/2021/SZSTIC); National Natural Science Foundation for Young Scientists of China (No. 81803398); Chinese Medicine Guangdong Laboratory (Hengqin Laboratory) (HOCML-B-2024001); University of Macau Multi-Year Research Grant (MYRG-CRG-2022-00006-FST)en_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
1-s2.0-S1878747924001661-main.pdf3.23 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

69
Citations as of Feb 9, 2026

Downloads

63
Citations as of Feb 9, 2026

SCOPUSTM   
Citations

9
Citations as of May 8, 2026

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.